binding affinity News and Research

RSS

Breakthrough in immunology: AbMAP’s novel approach to antibody modeling

Researchers developed AbMAP, a cutting-edge framework leveraging transfer learning to model antibody hypervariable regions, significantly improving design and immune repertoire analysis.

2 Jan 2025

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.

17 Nov 2024

Futuristic AI-powered virtual lab designs potent SARS-CoV-2 nanobodies

AI-human collaboration in a "Virtual Lab" successfully designs and experimentally validates nanobodies with enhanced binding to SARS-CoV-2 variants, offering a novel approach to interdisciplinary research.

14 Nov 2024

Virtual screening yields small molecules to enhance cancer immunotherapy

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine researchers.

7 Nov 2024

Researchers develop the first polymer-based therapeutic for Huntington’s disease

Breakthrough polymer-based therapy shows promise in reversing Huntington's disease symptoms by preventing toxic protein clumps and enhancing neuronal survival.

4 Nov 2024

New pathway discovery explains MRSA's high-level antibiotic resistance

Researchers have discovered a new cell division pathway in MRSA that enables high-level resistance to β-lactam antibiotics, marking a critical insight into the persistence of these 'superbugs'.

3 Nov 2024

New glucose-sensitive insulin NNC2215 could transform diabetes care by lowering hypoglycemia risk

NNC2215, a glucose-sensitive insulin, offers improved glycemic control by dynamically adjusting to blood sugar levels, reducing hypoglycemia in diabetes care.

18 Oct 2024

Understanding SARS-CoV-2's viral strategies for infection

This new article publication from Acta Pharmaceutica Sinica B, discusses how SARS-CoV-2 ORF10 hijacking ubiquitination machinery reveals potential unique drug targeting sites.

26 Sep 2024

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.

From Johnson & Johnson 24 Sep 2024

Study paves way for revolutionizing the management of muscle disorders

The type 1 ryanodine receptor (RyR1) is an important calcium release channel in skeletal muscles essential for muscle contraction.

18 Sep 2024

PPARs and PROTACs: A new strategy in cancer therapeutics

The growing challenge in cancer therapy lies in overcoming tumor heterogeneity, drug resistance, and associated side effects.

13 Sep 2024

SwRI develops a unique technology to screen new DNA-targeting therapeutics

Southwest Research Institute (SwRI) has developed a unique technology to screen new DNA-targeting therapeutics designed to treat cancer and other diseases.

19 Aug 2024

Study elucidates mechanisms behind G protein selectivity and efficacy in adenosine A2A receptor

In a groundbreaking study, a multinational research team led by Dr. Adnan Sljoka (RIKEN) and Prof. Akio Kitao (Tokyo Tech), in collaboration with Prof. Scott Prosser (University of Toronto), has carried out experimental and computational studies to elucidate the mechanisms behind G protein selectivity and efficacy in the human adenosine A2A receptor (A2AR).

1 Aug 2024

High mutation count in new COVID-19 variants does not increase immune evasion, study finds

New research from UNC Charlotte's Center for Computational Intelligence to Predict Health and Environmental Risks (CIPHER) has found that the two recent and prevalent strains of the virus that cause COVID-19, SARS-CoV-2 variants BA.2.86 and JN.1, are not significantly better than their predecessor Omicron at evading immune responses and causing infections despite having a high number of mutations compared to Omicron.

19 Jul 2024